35 Member Networks and Programs Receive Commendations in 2026 for Research Performance

Amended Trial: Lova Sun Describes Important Changes to the EA3231 Study for Patients With BRAF-Mutated Differentiated Thyroid Cancer

November 19, 2026

INTerpath-001 and Personalized mRNA Vaccination in Resected High-Risk Melanoma

November 19, 2026

Amended Trial: Lova Sun Describes Important Changes to the EA3231 Study for Patients With BRAF-Mutated Differentiated Thyroid Cancer

November 19, 2026

INTerpath-001 and Personalized mRNA Vaccination in Resected High-Risk Melanoma

November 19, 2026

35 Member Networks and Programs Receive Commendations in 2026 for Research Performance

Evaluation Form

35 Member Networks and Programs Receive Commendations in 2026 for Research Performance

Each year, the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) conducts an Institution Evaluation in which a subset of Principal Investigator (PI) Committee members and senior administrators meet to evaluate the performance of ECOG-ACRIN member networks and programs. The exceptional staff in the Membership Department facilitates the process—encompassing 1338 individual research institutions, comprising 123 research programs. Through this annual review, principal investigators and research personnel stay informed about the many scientific and administrative components that comprise ECOG-ACRIN's expectations for retaining membership in the Group. In addition, the evaluation ensures that member institutions maintain ECOG-ACRIN's high standards for conducting cancer research with and through the Group.

Data from the previous calendar year (2025) was evaluated. The following areas are part of the review: accrual, clinical data quality and timeliness, compliance with requirements for submission of laboratory samples and images, scientific leadership, administrative contribution, and compliance with policies of both ECOG-ACRIN and the National Cancer Institute (NCI) through its National Clinical Trials Network (NCTN) audit process. The review committee is blinded to the identity of the institutions during this initial evaluation when they give a numerical rating to these categories. However, final unblinded assessments are based on objective data and discussions on the unique aspects of each institution that cannot be captured in a numerical rating.

For 2026, the review committee voted to commend the following 35 networks and NCI Community Oncology Research Programs (NCORPs). Group Co-Chairs Peter J. O'Dwyer, MD, and Mitchell D. Schnall, MD, PhD, recognized them during the Fall 2026 Group Meeting General Session.

Overall Outstanding Performance

Institution

Principal Investigator

Administrator

Aultman Health System/Timken Family Cancer Center

Sunitha Vemulapalli, MD

Mary Amos, RN, BSN

Medical College of Wisconsin/MCW Cancer Center

Mehdi H. Hamadani, MD

Cassandra Gill, BA

Metro Minnesota Community Oncology Research Consortium NCORP

David M. King, MD

Pamela Felix, RN

The University of Texas/MD Anderson Cancer Center

In Transition

Shunte' Scott, MHA, BS

University of Massachusetts/UMass Memorial Medical Center - University Campus

Jan Cerny, MD, PhD

Ashley Robichaud, RN, BSN

University of Pennsylvania/Abramson Cancer Center

Jennifer R. Eads, MD

Kate S. Barbour, MS

University of Washington/Fred Hutchinson Cancer Center

Evan Y. Yu, MD

Maggie So, MPH

Washington University at St. Louis/Siteman Cancer Center

Barry A. Siegel, MD

Robin L. Haverman, BS

 

Scientific Contribution and Lab Sample Submission

Institution

Principal Investigator

Administrator

Mount Sinai Health System/The Tisch Cancer Institute

Joseph A. Sparano, MD

Shakira N. Forde, MS

 

Scientific Contribution and Lab Sample and Imaging Submission

Institution

Principal Investigator

Administrator

Montefiore Academic Community NCORP

Balazs Halmos, MD

Krysten Brown

 

Scientific Contribution and Administrative Participation

Institution

Principal Investigator

Administrator

Fox Chase Cancer Center

Hossein Borghaei, DO

Mary O'Rourke

Johns Hopkins University/The Sidney Kimmel Comprehensive Cancer Center

Julie R. Brahmer, MD

Judy Murray, BS

University of North Carolina at Chapel Hill/UNC Lineberger Comprehensive Cancer Center

Siddharth Sheth, DO, MPH

Jessica Huamani-Bundy, MS

University of Wisconsin/UW Carbone Cancer Center

Kari B. Wisinski, MD

Jordan T. Nelson

 

Scientific Contribution

Institution

Principal Investigator

Administrator

Duke University/Duke Cancer Institute

Daniel P. Barboriak, MD

Phillip N. Jeffries, BS

Memorial Sloan Kettering Cancer Center

Eytan M. Stein, MD

Edwin Zambrano-Acosta, MS

University of California Irvine/Chao Family Comprehensive Cancer Center

Ling Gao, MD, PhD

Michelle Tran

Yale University/Yale Cancer Center

Barbara A. Burtness, MD

Osarieme Oni, MS

 

Administrative Participation

Institution

Principal Investigator

Administrator

Thomas Jefferson University /Sidney Kimmel Comprehensive Cancer Center

Steven J. Cohen, MD

Pam Touchstone, BSN, MBA

 

Accrual, Scientific Contribution, and Lab Sample Submission

Institution

Principal Investigator

Administrator

Emory University/Winship Cancer Institute

Michael C. Lowe, MD, MA

Krystal Thomas, BS

New York University/Laura and Isaac Perlmutter Cancer Center at NYU LangoneHealth

Catherine S. Diefenbach, MD

Melanie Huber, MPH

 

Accrual, Scientific Contribution, and Administrative Participation

Institution

Principal Investigator

Administrator

Northwestern University/Robert H. Lurie Comprehensive Cancer Center

Al B. Benson III, MD

Ericka Chant, MPH

Rutgers Cancer Institute of New Jersey

Neil D. Palmisiano, MD

Cristina Jimenez-Ortigosa, PhD

Stanford University/Stanford Cancer Institute

Melinda L. Telli, MD

Martina Steffen, MS

Wisconsin NCORP

Kurt R. Oettel, MD

Mari K. Erickson, BA

 

Accrual, Scientific Contribution, Administrative Participation, and Lab Sample Submission

Institution

Principal Investigator

Administrator

The Ohio State University/The James Comprehensive Cancer Center

James W. Rocco, MD, PhD

Meghan Wyse, PhD

 

Accrual, Scientific Contribution, Administrative Participation, and Imaging Submission

Institution

Principal Investigator

Administrator

Harvard University/Dana-Farber/Harvard Cancer Center

Frank S. Hodi, MD

Nicole L. Hackett, MS

Moffitt Cancer Center

Jhanelle E. Gray, MD

Victoria Kryliouk, DHSc, MSHS, CCRP

 

Accrual and Scientific Contribution

Institution

Principal Investigator

Administrator

Mayo Clinic Cancer Center

Thomas M. Habermann, MD

Mitchell Perrizo

 

Accrual and Lab Sample and Imaging Submission

Institution

Principal Investigator

Administrator

University of Oklahoma Health Sciences Center

Jennifer L. Holter-Chakrabarty, MD

Juanita Ortiz

 

Accrual and Imaging

Institution

Principal Investigator

Administrator

Aurora NCORP

Thomas J. Saphner, MD

Geraldine Lara

 

Accrual

Institution

Principal Investigator

Administrator

Case Western Reserve University

Paolo F. Caimi, MD

LaToya Strickland

Mobile Infirmary Medical Center

Furhan Yunus, BS, MD

Alyssa Zediker

University of Michigan/UM Comprehensive Cancer Center

Thomas M. Enzler, MD, PhD

Linda Charles

The University of Texas Southwestern/Harold C. Simmons Comprehensive Cancer Center

David E. Gerber, MD

Erin Williams

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Please DO NOT include personal medical information, diagnoses, treatment details, medical record numbers, or other sensitive health information in this form.